Ghassan Abou-Alfa, MD, MBA

Cheng A-L et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76(4):862-73. Abstract

Lau G et al. Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC). ASCO 2023;Abstract 4004.

Lau G et al. Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC). ASCO 2023;Abstract 4073.

Sangro B et al. Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. ESMO GI 2023;Abstract SO-15.

Qin S et al. Camrelizumab (C) plus rivoceranib (R) vs sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase 3 trial. ESMO 2022;Abstract LBA35.

Daneng Li, MD

Alden SL et al. Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade. ASCO 2023;Abstract 4091.

Chow P et al. IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. AACR 2023;Abstract CT003.

Finn RS et al. Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study. Gastrointestinal Cancers Symposium 2023;Abstract 518.

Ikeda M et al. A phase 1b study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma. ASCO 2023;Abstract 4075.

Kaseb AO et al. Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in the United States (US): Final analysis of the prospective, observational REFINE study. ASCO 2023;Abstract e16114.

Kudo M et al. Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. ASCO 2023;Abstract 4002.

Sohal D et al. Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant. ASCO 2023;Abstract TPS4188.

Woo SM et al. Immunotherapy use prior to liver transplant in patients with hepatocellular carcinoma. Curr Oncol 2022;29(12):9813-25. Abstract